Inflammation/Immunology

Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases.

ανβ6 Integrin ligand-2 is a ανβ6 integrin ligand.

MPO-IN-5 (compound 1) is a potent, irreversible MPO (myeloperoxidase) inhibitor. MPO-IN-5 inhibits MPO peroxidation and hERG binding, with IC₅₀ values of 0.22 and 2.8 μM, respectively. MPO-IN-5 shows rapid kinetics of inhibition, with enzyme inactivation rate (k_inact/K_i) of 23000 M⁻¹s⁻¹.

Anti-IL-19 Antibody is a monoclonal antibody that targets IL-19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-19 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).

SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis.

FXb is an immunizing and functionalized hapten and can be used for protein bioconjugates preparation.

FR 111142 is an angiogenesis inhibitor (IC₅₀ = 18.4 μM) and has anti-inflammatory activity (IC₅₀ = 20.6 μM). FR 111142 inhibits capillary-like tube formation as well as nitric oxide production in LPS (HY-D1056)-activated murine macrophages. FR 111142 enhances catabolism of low-density lipoprotein (LDL). FR 111142 does not induce significant cytotoxicity in human endothelial progenitor cells, nor affect cell viability of murine macrophages. FR 111142 can be used for the research of cancer, inflammatory diseases.

RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC₅₀ = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC₅₀ ＞ 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS).

NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a K_d of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU (HY-B2130A)-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout.

COX-2/CaV2.2-IN-1 is an orally active and selective dual COX-2/CaV2.2 inhibitor, exhibiting a COX-2 IC₅₀ of 0.26 μM and a CaV2.2 IC₅₀ of 0.29 μM. COX-2/CaV2.2-IN-1 suppresses inflammatory responses and inflammatory mediator (IL-6, TNF-α, NO) production. COX-2/CaV2.2-IN-1 produces pronounced analgesic effects in diverse models of inflammatory, neuropathic, and visceral pain. COX-2/CaV2.2-IN-1 can be used for the research of chronic pain.

Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Phenylethanolamine A-d₃ is a deuterium labeled Phenylethanolamine A. Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.

DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.

N-(3-Oxohexanoyl)-L-homoserine lactone-d₂ (OHHL-d₂) is the deuterated-labeled N-(3-Oxohexanoyl)-L-homoserine lactone (HY-W008806). N-(3-Oxohexanoyl)-L-homoserine lactone (OHHL; N-(3-Oxohexanoyl)homoserine lactone) is a specific agonist of LuxR-type transcription factor CarR with a K_d of 1.8 μM. N-(3-Oxohexanoyl)-L-homoserine lactone activates CarR by inducing protein multimerization, promoting its binding to target DNA sequences in the carR-carA intergenic region, thereby upregulating the transcription of carbapenem biosynthesis genes. N-(3-Oxohexanoyl)-L-homoserine lactone acts as a quorum sensing signal molecule, enabling bacteria to coordinate the production of carbapenem antibiotics in a cell density-dependent manner. N-(3-Oxohexanoyl)-L-homoserine lactone is used to study bacterial quorum sensing mechanisms, especially the secondary metabolism and virulence factor regulatory pathways of Erwinia carotovora and Yersinia enterocolitica.

TLR7/8 antagonist 1 (Compound 16c) is a competitive TLR7/8 antagonist with IC₅₀ values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β.

13(R),14(R)-epoxy Fluprostenol isopropyl ester is a Prostaglandin derivative.

PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.

Escin IIb, isolated from horse chestnut, the seeds of Aesculus hippocastanum L., has positive effects on acute inflammation in animals. Escin IIb showed potent protective effects against ethanol-induced gastric mucosal lesions.

TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke.

TNF-α-IN-28 (compound 4ea) is a TNF-α and NF-κB inhibitor with anti-inflammatory activity. TNF-α-IN-28 inhibits TNF-α and NF-κB expression. TNF-α-IN-28 interacts with TNF-α dimer.